Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

pharmaphorum

MARCH 25, 2024

FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma

Antibody 111

Antibody Marketing 111

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 186

Antibody Marketing Drugs 186

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

Roots Analysis

FEBRUARY 27, 2024

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period.

Antibody 40

Antibody Marketing Drugs Contract Manufacturing 40

Drug Discovery World

APRIL 22, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. The post Webinar: How can we develop better therapeutic antibodies?

Antibody 52

Antibody Development Gene Therapy Marketing 52

Drug Discovery World

JANUARY 4, 2023

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts. The post Partnerships and collaborations fuel antibodies market growth appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Marketing Drugs Development 52

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

Antibody 59

Antibody FDA Approval Drugs Development 59

Drug Discovery World

JULY 25, 2023

This 24-page eBook sponsored by Carterra Bio examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector.

Antibody 52

Antibody Marketing Drugs Development 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. According to preliminary data, the antibody has demonstrated enhanced efficacy and reduced toxicity versus other treatments for HER2+ cancer indication. .

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

BioTech 365

JUNE 17, 2022

The global antibodies contract manufacturing market is expected to reach from USD 13.4 Rise in demand for the production of therapeutic antibodies … Continue reading → billion in 2022 to USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030.

Contract Manufacturing 52

Contract Manufacturing Antibody Manufacturing Marketing 52

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.

Antibody 81

Antibody FDA Approval Drugs Development 81

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.

Antibody 130

Antibody Licensing Licensing Containment 130

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Pharmaceutical Technology

JANUARY 23, 2023

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Antibody 130

Antibody Medicine Development Drugs 130

Pharmaceutical Technology

APRIL 3, 2023

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). The human immunoglobulin G1 (IgG(1)) monoclonal antibody adalimumab works by targeting tumour necrosis factor alpha (TNF-a).

Marketing 264

Marketing Medicine Packaging Packaging 264

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The latest deal will grant KangaBio an exclusive licence for the use of the antibody to carry out research, development, production and marketing of immunotherapy products.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Additionally, WuXi Biologics will help the company with the development of the anti-USAG-1 antibody for Investigational New Drug (IND) application.

Antibody 130

Antibody Development Bioassay Manufacturing 130

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing 264

Marketing Vaccination Vaccine Development 264

Pharmaceutical Technology

JANUARY 18, 2023

The National Medical Products Administration (NMPA) of China has approved Shanghai Henlius Biotech ’s monoclonal antibody Hansizhuang (serplulimab injection) along with carboplatin and etoposide to treat extensive stage small cell lung cancer (ES-SCLC). Hansizhuang is the company’s first self-developed anti-PD-1 monoclonal antibody (mAb).

Antibody 130

Antibody Drugs Production Marketing 130

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

Antibody 130

Antibody Drugs Development Medicine 130

Roots Analysis

DECEMBER 11, 2022

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Antibody drug conjugates market is presently an established therapeutic concept with 11 approved products.

Antibody 40

Antibody Marketing Contract Manufacturing Drugs 40

Drug Discovery World

JULY 26, 2023

This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector.

Antibody 52

Antibody Marketing Drugs 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group. According to the agreement, CSPC will receive a $7.5m

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Drug Discovery World

MAY 7, 2024

DDW Editor Reece Armstrong speaks to David Chau , Global Bioprocess Application Specialist, Separation and Purification Sciences Division, 3M, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes. RA: What are some of the current limitations for producing mAbs? He earned his Ph.D

Antibody 59

Antibody Production Manufacturing Engineer 59

Roots Analysis

AUGUST 9, 2023

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. The market is currently characterized by well-established firms.

Antibody 52

Antibody Marketing Development Engineer 52

Pharmaceutical Technology

MARCH 16, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for argenx’s Vyvgart (efgartigimod alfa-fcab) to treat generalised myasthenia gravis (gMG). It attaches to the neonatal Fc receptor (FcRn) that results in circulating immunoglobulin G (IgG) autoantibodies reduction.

Marketing 130

Marketing Antibody Trials Medicine 130

Pharmaceutical Technology

NOVEMBER 16, 2022

Clinical-stage biopharmaceutical companies NextCure and LegoChem Biosciences have signed a collaboration and co-development agreement to develop a B7-H4 antibody drug conjugate (ADC), and features options for two further targets. Furthermore, NextCure signed a supply agreement for Keytruda with Merck.

Antibody 130

Antibody Development Drugs Production 130

Drug Discovery World

FEBRUARY 15, 2024

DDW Editor Reece Armstrong speaks to Tracy M Woody , President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. RA: Naloxone is currently widely available on the market and can reverse an opioid overdose. Yet opioid deaths are high in the US.

Antibody 59

Antibody FDA Approval Drugs Development 59

Pharmaceutical Technology

MAY 22, 2023

Biogen and Eisai have submitted a marketing authorisation application (MAA) to the UK’s medicines and healthcare products regulatory agency (MHRA) for lecanemab to treat early Alzheimer’s disease (AD).

Marketing 130

Marketing Antibody Licensing Licensing 130

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 Pfizer maintained its third-place position in the market in 2022, reporting a market capitalization of $287.6 witnessed the biggest market capitalization growth of 45.3% trillion to $3.61 billion on Dec 31, 2022.

Marketing 195

Marketing Sales Vaccination Vaccine 195

pharmaphorum

JANUARY 15, 2021

South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first part of a phase 2/3 trial showing it could cut recovery times and chances of progression from moderate to more severe disease. reported with placebo. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Antibody 97

Antibody Trials Marketing Regulation 97

Drug Discovery World

MARCH 8, 2024

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.

Antibody 52

Antibody Trials In-Vitro Clinical Trials 52

Drug Discovery World

SEPTEMBER 6, 2023

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature. In 2022, there were 156 antibody-focused deals with a value of $57.3 In 2022, there were 156 antibody-focused deals with a value of $57.3 billion, up 40% from 2021. billion, up 40% from 2021.

Antibody 52

Antibody Development Sales Manufacturing 52